Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

NCT05724329 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinomas

Interventions

DRUG: Tislelizumab + Dasatinib + Quercetin (neoadjuvant)
PROCEDURE: surgery
DRUG: Tislelizumab + Dasatinib + Quercetin (adjuvant)

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University